Cost-effectiveness studies in ovarian cancer

International Journal of Gynecological Cancer

Volumn 13, Issue SUPPL. 2, 2003, Pages 212-219

  Szucs, Thomas D ^a,c   Wyss, P ^b   Dedes, K J ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Chemotherapy; Cost effectiveness; Costs; Ovarian cancer; Screening

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; PACLITAXEL;

CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SCREENING; CONFERENCE PAPER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; MEDICAL DECISION MAKING; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; ULTRASOUND;

EID: 1242275137     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1136/ijgc-00009577-200311001-00015     Document Type: Conference Paper

References (47)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002;38:99-166.
3. Fuchs VR, Garber AM. The new technology assessment. N Engl J Med 1990;323:673-7.
4. Gold MR. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
5. Drummond MF. Methods for the Economic Evaluation of Health Care Programmes. Oxford Medical Publications. Oxford, New York: Oxford University Press, 1997.
6. Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10.
7. Einhorn N, Bast R, Knapp R, Nilsson B, Zurawski V Jr, Sjovall K. Long-term follow-up of the Stockholm screening study on ovarian cancer. Gynecol Oncol 2000;79:466-70.
8. Creasman WT, DiSaia PJ. Screening in ovarian cancer. Am J Obstet Gynecol 1991;165:7-10.
9. Urban N, Drescher C, Etzioni R, Colby C. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials 1997;18:251-70.
10. Westhoff C, Randall MC. Ovarian cancer screening: potential effect on mortality. Am J Obstet Gynecol 1991;165:502-5.
11. Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. Health Technol Assess 1998;2:1-84.
12. Menon U, Jacobs IJ. Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer 2001;11:3-6.
13. Tengs TO, Berry DA. The cost-effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Dis Manage Clin Outcomes 2000;1:15-24.
14. Max W, Rice DP, Sung HY, Michel M, Breuer W, Zhang X. The economic burden of gynecologic cancers in California, 1998. Gynecol Oncol 2003;88:96-103.
15. Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol 1996;49:95-103.
16. Khan ZM, Rascati KL, Koeller JM. Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer. Pharmacoeconomics 1999;16:43-57.
17. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
18. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
19. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-92.
20. du Bois A, Neijt JP, Thigpen JT. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care? Ann Oncol 1999;10:35-41.
21. Ozols RF. Update on the management of ovarian cancer. Cancer J 2002;8:S22-30.
22. Messori A, Trippoli S, Becagli P, Tendi E. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis. Cancer 1996;78:2366-73.
23. Berger K, Fischer T, Szucs TD. Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective. Eur J Cancer 1998;34:1894-901.
24. Covens A, Boucher S, Roche K et al. Is paclitaxel and cisplatin a cost-effective first-line therapy for advance ovarian carcinoma? Cancer 1996;77:2086-91.
25. Elit LM, Gafni A, Levine MN. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. J Clin Oncol 1997;15:632-9.
26. McGuire W, Neugut AI, Arikian S, Doyle J, Dezii CM. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997;15:640-5.
27. Ortega A, Dranitsaris G, Sturgeon J, Sutherland H, Oza A. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 1997;66:454-63.
28. Neymark N, Gorlia T, Adriaenssen I, Baron B, Piccart M. Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. Pharmacoeconomics 2002;20:485-97.
29. Walker H, Stuart G, Bacon M et al. Comparative cost-effectiveness of paclitaxel-cisplatin (TP) vs cyclophosphamide-cisplatin (CP) in women with advanced epithelial ovarian cancer: Results from a randomized trial. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. New Orleans: American Society of Clinical Oncology, 2000, 150.
30. Woronoff-Iemsi MH, Menat C, Limat SJ, Madroszyk-Flandin A, Jacquet M, Merrouche Y. Cost effectiveness analysis of paclitaxel in first line chemotherapy of advanced ovarian cancer. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. San Francisco: American Society of Clinical Oncology, 2001, 844.
31. Kievit J, van de Velde CJ. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis. Cancer 1990;65:2580-7.
32. Desch CE, Lasala MR, Smith TJ, Hillner BE. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol 1992;10:200-9.
33. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 1991;324:160-8.
34. Welch HG, Larson EB. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989;321:807-12.
35. Desch CE, Hillner BE, Smith TJ, Retchin SM. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 1993;11:777-82.
36. Ozer H, Golomb HM, Zimmerman H, Spiegel RJ. Cost-benefit analysis of interferon α-2b in treatment of hairy cell leukemia. J Natl Cancer Inst 1989;81:594-602.
37. Rees GJ. Cost-effectiveness in oncology. Lancet 1985; 2:1405-8.
38. Doyle C, Stockler M, Pintilie M et al. Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 1997;15:1000-7.
39. Patnaik A, Doyle C, Oza AM. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost. Anticancer Drugs 1998;9:869-78.
40. Calhoun EA, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennett CL. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 2001;6: 441-5.
41. Calhoun EA, Bennett CL. Pharmacoeconomics of amifostine in ovarian cancer. Semin Oncol 1999;26:102-7.
42. Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection. Support Care Cancer 1997;5:489-99.
43. Kornblith AB, Thaler HT, Wong G et al. Quality of life of women with ovarian cancer. Gynecol Oncol 1995; 59:231-42.
44. Portenoy RK, Kornblith AB, Wong G et al. Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms. Cancer 1994;74:907-15.
45. Guidozzi F. Living with ovarian cancer. Gynecol Oncol 1993;50:202-7.
46. Smith DH, Adams JR, Johnston SR, Gordon A, Drummond MF, Bennett CL. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 2002;13:1590-7.
47. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.